Quan S. Ng

11 Hospital Crescent
Singapore, 169610, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Metastatic Count and Local Ablative Therapy Influence Survival Outcomes in Oligometastatic Nasopharyngeal Carcinoma Patients.

Metastatic Count and Local Ablative Therapy Influence Survival Outcomes in Oligometastatic Nasopharyngeal Carcinoma Patients.

Journal: Head & neck

Published: May 22, 2026

Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.

Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer.

Journal: Cancer research communications

Published: January 23, 2026

Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancer.

Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancer.

Journal: Cancer research communications

Published: January 23, 2026

EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.

EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 24, 2025

Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer.

Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal: JCO precision oncology

Published: June 21, 2024

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.

Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 24, 2024

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.

Journal: Cancer

Published: September 28, 2023

Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.

Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.

Journal: Cancer research

Published: September 01, 2023

Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer.

Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer.

Journal: JCO precision oncology

Published: October 14, 2022

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.

Journal: Translational lung cancer research

Published: September 11, 2022

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 01, 2022

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 16, 2022

Showing 1-12 of 65

Last Updated: 09/26/2026